Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Minerva Gastroenterologica e Dietologica

• Publication date

  2015-01-22

• Fields of study

  Medicine

• Identifiers
  PMID 25610998
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

  2015cited by this paper
• Inhibition of pancreatic tumoral cells by snake venom disintegrins.

  2015cited by this paper
• Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

  2014cited by this paper
• A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.

  2014cited by this paper
• Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

  2014cited by this paper
• An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition

  2014cited by this paper
• Genome‐wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT‐ROBO, ITGA2 and MET signaling

  2014cited by this paper
• Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop

  2013cited by this paper
• Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.

  2013cited by this paper
• Effects of integrin-targeted photodynamic therapy on pancreatic carcinoma cell.

  2013cited by this paper
• Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer‐initiating cells

  2013cited by this paper
• Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery

  2013cited by this paper
• Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study

  2013cited by this paper
• The Differentiation of Pancreatic Tumor-Initiating Cells by Vitronectin Can Be Blocked by Cilengitide

  2013cited by this paper
• The metastasis‐associated molecule C4.4A promotes tissue invasion and anchorage independence by associating with the alpha6beta4 integrin

  2013cited by this paper
• Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

  2013cited by this paper
• Effects and mechanism of integrin-β1 gene expression inhibited by shRNA in invasion of pancreatic carcinoma PANC-1 cells.

  2012cited by this paper
• Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

  2012cited by this paper
• αLβ2 Integrin is indispensable for CD8+ T‐cell recruitment in experimental pancreatic and hepatocellular cancer

  2012cited by this paper
• Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1)

  2012cited by this paper
• TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression.

  2012cited by this paper
• Interplay between β1-Integrin and Rho Signaling Regulates Differential Scattering and Motility of Pancreatic Cancer Cells by Snail and Slug Proteins*

  2012cited by this paper
• Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

  2012cited by this paper
• A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma

  2012cited by this paper
• Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

  2012cited by this paper
• A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

  2011cited by this paper
• Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

  2011cited by this paper
• Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

  2011cited by this paper
• α2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5

  2011cited by this paper
• Knockdown of the β1 integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis

  2011cited by this paper
• A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

  2011cited by this paper
• A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

  2011cited by this paper
• Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

  2011cited by this paper
• Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

  2011cited by this paper
• Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

  2011cited by this paper
• Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling.

  2011cited by this paper
• Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma

  2011cited by this paper
• Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma

  2010cited by this paper
• Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases

  2010cited by this paper
• Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

  2010cited by this paper
• Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.

  2010cited by this paper
• Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer

  2010cited by this paper
• Dual Effects of β3 Integrin Subunit Expression on Human Pancreatic Cancer Models

  2010cited by this paper
• Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.

  2009cited by this paper
• alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma.

  2009cited by this paper
• Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression

  2009cited by this paper
• Alterations in integrin expression modulates invasion of pancreatic cancer cells

  2009cited by this paper
• Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

  2009cited by this paper
• Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation.

  2008cited by this paper
• Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

  2008cited by this paper
• Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

  2008cited by this paper
• Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

  2008cited by this paper
• Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients

  2008cited by this paper
• Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

  2008cited by this paper
• Determination of the Ligand-Binding Specificities of the &agr;2&bgr;1 and &agr;1&bgr;1 Integrins in a Novel 3-Dimensional In Vitro Model of Pancreatic Cancer

  2007cited by this paper
• Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.

  2007cited by this paper
• Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

  2007cited by this paper
• Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.

  2007cited by this paper
• Cholecystokinin-2 receptor modulates cell adhesion through β1-integrin in human pancreatic cancer cells

  2006cited by this paper
• Integrin-linked kinase activity is associated with interleukin-1α-induced progressive behavior of pancreatic cancer and poor patient survival

  2006cited by this paper
• Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

  2006cited by this paper
• The α2β1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines

  2006cited by this paper
• Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.

  2005cited by this paper
• Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

  2005cited by this paper
• Immunohistochemical Detection of the β4 Integrin Subunit in Pancreatic Adenocarcinoma

  2005cited by this paper
• Colocalization of the Tetraspanins, CO-029 and CD151, with Integrins in Human Pancreatic Adenocarcinoma: Impact on Cell Motility

  2005cited by this paper
• Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro.

  2004cited by this paper
• Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

  2003cited by this paper
• Expression and Prognostic Roles of Integrins and Interleukin-1 Receptor Type I in Patients with Ductal Adenocarcinoma of the Pancreas

  2003cited by this paper
• Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer.

  2003cited by this paper
• A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

  2001cited by this paper
• Integrin-Mediated Differentiation of a Pancreatic Carcinoma Cell Line Is Independent of FAK or MAPK Activation Levels

  2001cited by this paper
• Alteration of integrins by interleukin-1alpha in human pancreatic cancer cells.

  2001cited by this paper
• A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.

  2000cited by this paper
• Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

  2000cited by this paper
• Beta1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells.

  2000cited by this paper
• Prognostic Value of Immunohistochemical Expression of Beta-1 Integrin in Pancreatic Carcinoma

  1999cited by this paper
• Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells.

  1999cited by this paper
• Increased expression of alpha6-integrin receptors and of mRNA encoding the putative 37 kDa laminin receptor precursor in pancreatic carcinoma.

  1997cited by this paper
• Retinoids inhibit adhesion to laminin in human pancreatic carcinoma cells via the alpha 6 beta 1-integrin receptor.

  1997cited by this paper
• Expression and Function of Receptors for Extracellular Matrix Proteins in Human Ductal Adenocarcinomas of the Pancreas

  1996cited by this paper
• Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas

  1995cited by this paper
• The alpha 6-integrin receptor in pancreatic carcinoma.

  1995cited by this paper
• Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma.

  1992cited by this paper
• Characterization of integrin chains in normal and neoplastic human pancreas

  1991cited by this paper

• Remodeling cancer stemness by collagen/fibronectin via the AKT and CDC42 signaling pathway crosstalk in glioma

  2021cites this paper
• Application of Peptides and Proteomicsin the Diagnosis and Management ofPancreatic Cancer

  2020cites this paper
• Fundamentals of protein and cell interactions in biomaterials.

  2017cites this paper
• High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma

  2017cites this paper